MacroGenics, Inc. is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for the treatment of cancer. The company utilizes proprietary technology platforms to generate product candidates, including antibody-drug conjugates (ADCs) and multi-specific antibodies known as DART and TRIDENT molecules. Its pipeline includes lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4, and MGC026 and MGC028, which are ADCs delivering topoisomerase I inhibitor payloads. MacroGenics retains economic rights to three FDA-approved therapies: ZYNYZ (retifanlimab-dlwr), MARGENZA (margetuximab-cmkb), and TZIELD (teplizumab-mzwv). The company collaborates with partners such as Gilead Sciences on MGD024, a bispecific DART molecule targeting CD123 and CD3. Founded in 2000, MacroGenics operates a commercial-scale cGMP antibody manufacturing facility and provides contract development and manufacturing services to third parties.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage macrogenics.com
Sector Healthcare IR page ir.macrogenics.com
Tags
antibody-drug conjugates, bispecific antibodies, t-cell engagers, oncology, hematology, immune checkpoint inhibitors, topoisomerase i inhibitors, contract manufacturing, DART, TRIDENT, lorigerlimab, MGC026, MGC028, MGC030, MGD024, ZYNYZ, retifanlimab-dlwr, MARGENZA, margetuximab-cmkb, TZIELD, teplizumab-mzwv, SYNtecan E, GlycoConnect
Press page —

Metrics

Valuation  
Market cap $ 246.561M
Market cap (USD) $ 246.561M
P/E -3.27
PEG —
P/BV 9.80
P/S 2.17
P/OCF -6.18
P/FCF -5.96
Dividend yield —
Turnover / mcap —
Returns  
ROE -86.9%
ROI -249.1%
ROIC -182.4%
Profit margin -49.9%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 55
Quality score -70.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 149.5M 149.962M 58.749M 151.941M 77.447M 104.883M 64.188M 60.121M 157.742M 91.88M 100.854M 47.797M 58.035M 63.826M
Net profit -74.62M -66.966M -9.058M -119.758M -202.115M -129.739M -151.811M -171.453M -19.626M -58.528M -20.14M -38.313M -260.835K 8.362M
Free cash flow -82.954M -72.079M -79.969M -90.582M -150.031M -117.804M -138.559M -178.188M -14.998M -55.06M -22.858M -36.331M -17.133M -7.522M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 1.61 3.25 9.62 6.71 16.05 22.86 10.88 12.7 19 20.44 30.97 35.07 27.43 —
Price performance 12m -0.5 -0.66 0.43 -0.58 -0.3 1.1 -0.14 -0.33 -0.07 -0.34 -0.12 0.28 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 2.76M 13.6M 29.6M 12.7M 23.1M 10.4M 56.2M 10.4M 4.31M 13.4M
↳ YoY growth +125.8% +393.6% +116.8% -56.9% +81.1% -55.0% +441.3% -81.6% -58.4% +210.4%
↳ 5y CAGR +46.1% +71.3% +34.1% +79.9% +30.3% +32.7% -18.9% -19.5% -10.3%
Lease liabilities (USD) — — 0.00 30.6M 29.2M 25.5M 34.8M 34M 37.5M 36.8M
Cash and deposits (USD) 84.1M 212M 220M 126M 181M 123M 109M 101M 183M 57.2M
Right-of-use assets (USD) — — 16.4M 20.2M 19.3M 16.6M 27.3M 23.8M 24.5M 22.9M
Cash flow detail
Operating cash flow (USD) -43.7M 14.4M -153M -134M -112M -144M -87M -78.2M -68.4M -81M
Purchases of property, plant and equipment (USD) -11.4M -29.4M -25M -4.29M -5.91M -6.2M -3.62M -1.76M -3.71M -1.91M
Change in receivables (cash effect) (USD) -1.54M -10.9M -15.9M 16.8M -10.3M 12.7M -45.8M 45.9M 6.06M -9.06M
Change in inventories (cash effect) (USD) — — — 0.00 0.00 -6.42M 55,000 230,000 -2.19M -7.91M
Change in payables (cash effect) (USD) 2.23M -1.54M 1.55M 787,000 3.72M 7.13M -10.9M 1.28M -1.53M -280,000
Income taxes paid (cash effect) (USD) — — — — — — 0.00 0.00 -944,000 —
Share-based compensation (USD) 12.2M 14.7M 16.5M 19.6M 20.7M 23.1M 20.4M 18.4M 29.4M 14.3M
Operating cash flow before change in receivables (USD) -42.1M 25.3M -137M -151M -102M -157M -41.1M -124M -74.4M -72M
Free cash flow (OCF - PPE - intangibles) (USD) -55.1M -15M -178M -139M -118M -150M -90.6M -80M -72.1M -83M
Income detail
Research and development expense (USD) 122M 147M 191M 195M 193M 215M 207M 167M 177M 147M
↳ 5y CAGR +24.3% +26.5% +32.6% +22.7% +14.5% +11.9% +7.1% -2.7% -1.9% -5.3%
Total comprehensive income (USD) — -19.6M -171M -152M -130M -202M -120M -9.06M -67M -74.6M
Comprehensive income to owners (USD) — -19.6M -171M -152M -130M -202M -120M -9.06M -67M -74.6M
Reported Feb 28, 2017 Feb 25, 2020 Feb 25, 2020 Feb 24, 2022 Feb 24, 2022 Feb 24, 2022 Mar 20, 2025 Mar 20, 2025 Mar 20, 2025 Mar 9, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

MacroGenics, Inc. — Regulation FD Disclosure Bull 1 Bear 0 Routine

On November 13, 2026, MacroGenics, Inc. (the “Company”) made available an updated version of the Company’s corporate presentation on its website, which reflects updated clinical program details. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing

•Completed MGC028 Phase 1 dose escalation; selected lead indication for dose optimization across two dose levels

•Reported interim results at ESMO in both Phase 1 study of MGC026 in heavily pretreated SCCHN patients and Phase 2 study of lorigerlimab in CCGC patients

•First patient dosed with MGC030 in Phase 1 study

•Strengthened Board with addition of two new independent directors with expertise in oncology drug discovery and development

•Cash, cash equivalents and marketable securities of $287.7 million as of September 30, 2026; cash runway guidance remains through 2028

ROCKVILLE, MD., November 12, 2026 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended September 30, 2026, and highlighted recent corporate progress.

“MacroGenics has made significant progress over the past year.

ROCKVILLE, MD, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management team will participate in the following investor conferences in November:

  • Stifel 2026 Healthcare Conference (New York, NY). MacroGenics’ President and CEO, Eric Risser, will participate in a fireside chat on Wednesday, November 11, at 10:00 am ET. MacroGenics’ management will also participate in one-on-one meetings.

  • 9th Annual Evercore Healthcare Conference (Coral Gables, FL). Mr. Risser will participate in a fireside chat on Monday, November 30, at 3:00 pm ET. MacroGenics’ management will also participate in one-on-one meetings.

Webcasts of these presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of the webcasts on its website for 30 days.

About MacroGenics, Inc. MacroGenics (the Company) is a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics’ technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company’s website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

Contacts: Jim Karrels, Senior Vice President, CFO 1-301-251-5172 [email protected] Argot Partners 1-212-600-1902 [email protected]

Primary Logo

Prompts

MacroGenics, Inc. (ticker MGNX), listed in United States.

ETFs Holding MacroGenics, Inc.

ETF Weight in ETF Shares Market value As of
VFMO 0.05% 219,190 $ 874.568K Aug 31, 2026
MSSM 0.00% 1,182 $ 4,716.18 Aug 31, 2026
DCOR 0.00% 3,958 $ 9,063.82 Nov 12, 2026
DFAS 0.00% 900 $ 2,061.00 Nov 12, 2026
DFAC 0.00% 1,871 $ 4,284.59 Nov 12, 2026
AVSC 0.00% 712 $ 1,545.04 Nov 16, 2026